Skip to main content
IMUGENE LIMITED logo

IMUGENE LIMITED — Investor Relations & Filings

Ticker · IMU ISIN · AU000000IMU9 LEI · 984500A5C9KF08EAF248 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,442 across all filing types
Latest filing 2021-12-07 Board/Management Inform…
Country AU Australia
Listing ASX IMU

About IMUGENE LIMITED

https://imugene.com

Imugene Limited is a clinical-stage immuno-oncology company focused on developing immunotherapies to activate the immune system against various cancers. The company’s pipeline features multiple platform technologies, including B-cell activating immunotherapies, oncolytic viruses, and CAR-T cell enhancement therapies. Key clinical candidates include HER-Vaxx, targeting HER2-positive gastric cancer, and PD1-Vaxx, a checkpoint inhibitor immunotherapy. Imugene is also advancing the CF33 oncolytic virus platform, which includes VAXINIA and CHECKvacc, alongside the onCARlytics program. The onCARlytics platform is designed to enable CAR-T cells to target solid tumors by inducing the expression of CD19 on cancer cell surfaces. These programs aim to address unmet needs in oncology by providing targeted, potent, and potentially less toxic alternatives to conventional treatments.

Recent filings

Filing Released Lang Actions
Change in Joint Company Secretary 1 page 98.2KB
Board/Management Information Classification · 100% confidence The document is an ASX announcement about a change in the company's joint company secretary. It mentions the resignation of one secretary and the appointment of another. There is no financial data, no report attached or referenced, and no mention of financial results or regulatory filings beyond the personnel change. This fits the category of Board/Management Information (MANG), which covers announcements of changes in senior management or board members. The document length is short and focused solely on management change, confirming the classification.
2021-12-07 English
Update on Clinical Trial of Oncolytic Virotherapy CHECKvacc 5 pages 163.7KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Imugene Limited providing an update on the Phase I clinical trial of their oncolytic virotherapy candidate CHECKvacc. It details the trial design, objectives, and background information about the therapy and the principal investigator. There are no financial statements, earnings data, or regulatory filings related to financial performance. The content is focused on clinical trial progress and scientific information rather than financial or governance matters. It is not a report publication announcement since it contains substantive information rather than just a notice. The document fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement about clinical trial progress that does not fit into other specific categories such as earnings release, management report, or capital update.
2021-12-06 English
Appendix 2A 20 pages 375.8KB
Regulatory Filings Classification · 95% confidence The document is an Appendix 2A form, which is an application for quotation of securities on the ASX (Australian Securities Exchange). It details the issuance and quotation of securities resulting from options exercised or convertible securities converted. The document is a regulatory announcement related to securities quotation and issuance, not a financial report or earnings release. It is a formal regulatory filing notifying the exchange and the market of new securities to be quoted. This type of document fits best under the category of Regulatory Filings (RNS), as it is a general regulatory announcement and does not fall under more specific categories like Capital/Financing Update or Share Issue/Capital Change, which are typically used for announcements of new capital raisings or share issues rather than the formal application for quotation of securities.
2021-12-05 English
Appendix 2A 20 pages 376.0KB
Capital/Financing Update Classification · 95% confidence The document is an Appendix 2A form, which is an application for quotation of securities on the ASX (Australian Securities Exchange). It details the issuance and quotation of securities resulting from options being exercised or convertible securities being converted. The document is a regulatory announcement related to capital markets activity, specifically the listing or quotation of new securities. It is not a financial report, earnings release, or management discussion. It is also not a proxy, AGM material, or legal proceeding. The document is a formal regulatory filing notifying the exchange and market of new securities quotation. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes such as new securities issuance and quotation.
2021-11-25 English
Results of Meeting Percentages 2 pages 158.1KB
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an ASX announcement presenting the results percentages of an Annual General Meeting (AGM) held on 23 November 2021. It details the voting outcomes on specific resolutions, including the remuneration report, re-election of a director, and ratification of a previous equity issuance. The document references compliance with Listing Rule 3.13.2 and Section 251AA of the Corporations Act 2001, which govern disclosure of voting results. The content is focused on the official results of shareholder votes at the AGM, not the AGM materials themselves or the full annual report. The document length is short (2247 characters) and it provides detailed voting results, which aligns with the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2021-11-22 English
Change of Director's Interest Notice (AH) 3 pages 178.4KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a director, including dates, number of shares/options acquired or disposed, and nature of the transactions. This matches the definition of a Director's Dealing report, which involves reporting personal share transactions by company directors and executives (insider trades). The document is not an announcement of a report, nor a full financial report, but a regulatory disclosure of director share transactions.
2021-11-21 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.